respiratory syncytial virus subgroup B stabilized prefusion F protein 847B

Respiratory syncytial virus subgroup B stabilized prefusion F protein 847B is a recombinant protein antigen designed for use in vaccines against respiratory syncytial virus (RSV). It consists of the fusion (F) protein from RSV subgroup B, engineered and stabilized in its prefusion conformation. The F protein is a critical surface glycoprotein that mediates viral entry into host cells and is the primary target for neutralizing antibodies. Stabilizing the protein in the prefusion state, rather than the postfusion state, preserves highly potent epitopes (such as Site Ø) that elicit a superior immune response. This specific antigen, 847B, is typically utilized as a component of bivalent RSV vaccine candidates (e.g., GSK3844766A or GSK3888550A) to provide broad protection against both major RSV subgroups (A and B). The development of this antigen has been led by GSK, with Fondazione Penta Ets serving as a key collaborator in clinical research, particularly for pediatric populations.

Other names

RSV subgroup B stabilized prefusion F protein 847BRSV subgroup B preF 847BRSV subgroup B stabilized prefusion F protein